Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Head of Development

Head of Pharm Ops and Tech

EVP, Human Resources

EVP Chief Legal Officer

Head of Global Product Strat.

EVP, Chief Financial Officer

Chief Accounting Officer

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the Unit...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-02	Premium	sold	Premium	Premium	Premium	Head of Development
2024-04-01	Premium	acquired	Premium	Premium	Premium	Head of Pharm Ops and Tech
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Head of Pharm Ops and Tech
2024-02-22	Premium	sold	Premium	Premium	Premium	Head of Development
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP, Human Resources
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP Chief Legal Officer
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	Head of Pharm Ops and Tech
2024-02-16	Premium	acquired	Premium	Premium	Premium	Head of Global Product Strat.
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	Head of Global Product Strat.
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	Head of Development
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	Chief Accounting Officer
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Human Resources
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	EVP Chief Legal Officer
2024-02-16	Premium	sold	Premium	Premium	Premium	Head of Development
2024-02-16	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-02-16	Premium	acquired	Premium	Premium	Premium	Head of Pharm Ops and Tech
2024-02-16	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-02-16	Premium	acquired	Premium	Premium	Premium	Head of Development
2024-02-15	Premium	bought	Premium	Premium	Premium	-
2024-02-12	Premium	sold	Premium	Premium	Premium	Head of Development
2024-02-09	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-02-09	Premium	sold (taxes)	Premium	Premium	Premium	EVP Chief Legal Officer

BIIB - Biogen Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for BIIB